Hepatitis B Trial, Recruiting NCT05937178 Sponsor: Huashan Hospital Condition: Hepatitis B
Back to Hepatitis B

Hepatitis B Trial, Recruiting

NCT05937178
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with chronic hepatitis B, meaning you have tested positive for the hepatitis B surface antigen for at least 6 months, or have liver biopsy results showing hepatitis B-related changes within the past year
  • You are between 18 and 80 years old
  • You are willing to read and sign a consent form agreeing to take part

AND you fall into one of these three groups:

  • Group A: You have never been treated for hepatitis B, your virus levels and liver enzyme levels meet certain thresholds, AND at least one of the following applies: you are over 30 with a family history of liver cirrhosis or liver cancer; you are 30 or under with a family history of liver cirrhosis or liver cancer; or a liver stiffness test shows early scarring but you are 30 or under with no family history of those conditions (confirm with trial site for exact test values)
  • Group B: You have never been treated for hepatitis B, you do not have cirrhosis, and your virus levels and liver enzyme results fall within certain ranges — including some people with normal liver enzymes who are over 30 with a family history of cirrhosis or liver cancer, or who have early liver scarring on testing (confirm with trial site for exact values)
  • Group C: You have previously been treated with a standard hepatitis B antiviral tablet (such as entecavir or tenofovir) for at least 48 weeks but have not responded fully to treatment, and you are planning to continue or change your treatment

Who may not be able to join:

  • You have a history of not following medical instructions or sticking to treatment plans
  • You are currently taking a medication that is not allowed in this trial and have not completed at least a 30-day "washout" period off that medication, or you have had a known allergic reaction to the study drug or its ingredients
  • Your doctor feels that for any other medical reason or based on your treatment history, this trial would not be appropriate or safe for you

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Wenghong Zhang, MD, Huashan Hospital

Phone: 13801844344

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Huashan Hospital
Registry
ClinicalTrials.gov
Start date
31 January 2023
Est. completion
31 January 2029

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The proportion of patients with HBV DNA <20 IU/ml; The proportion of patients with HBV DNA <20 IU/ml; The proportion of patients with HBV DNA <20 IU/ml; Change from baseline in Estimated Glomerular Filtration Rate by the Cockcroft-Gault Formula (eGFR-CG); Change from baseline in Estimated Glomerular Filtration Rate by the Cockcroft-Gault Formula (eGFR-CG); Change from baseline in Estimated Glomerular Filtration Rate by the Cockcroft-Gault Formula (eGFR-CG); Change from baseline in Estimated Glomerular Filtration Rate by the Cockcroft-Gault Formula (eGFR-CG)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov